CN107690427B - 一种制备恩杂鲁胺的新方法 - Google Patents

一种制备恩杂鲁胺的新方法 Download PDF

Info

Publication number
CN107690427B
CN107690427B CN201680033803.4A CN201680033803A CN107690427B CN 107690427 B CN107690427 B CN 107690427B CN 201680033803 A CN201680033803 A CN 201680033803A CN 107690427 B CN107690427 B CN 107690427B
Authority
CN
China
Prior art keywords
compound
formula
reaction
impurity
enzalutamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680033803.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN107690427A (zh
Inventor
廖苑秀
郭俊徹
施雯莉
陈尚鸿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scinopharm Taiwan Ltd
Original Assignee
Scinopharm Taiwan Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scinopharm Taiwan Ltd filed Critical Scinopharm Taiwan Ltd
Publication of CN107690427A publication Critical patent/CN107690427A/zh
Application granted granted Critical
Publication of CN107690427B publication Critical patent/CN107690427B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201680033803.4A 2015-06-10 2016-06-08 一种制备恩杂鲁胺的新方法 Active CN107690427B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562173814P 2015-06-10 2015-06-10
US62/173,814 2015-06-10
PCT/SG2016/050267 WO2016200338A1 (en) 2015-06-10 2016-06-08 A novel process for preparing enzalutamide

Publications (2)

Publication Number Publication Date
CN107690427A CN107690427A (zh) 2018-02-13
CN107690427B true CN107690427B (zh) 2020-08-11

Family

ID=57503792

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680033803.4A Active CN107690427B (zh) 2015-06-10 2016-06-08 一种制备恩杂鲁胺的新方法

Country Status (10)

Country Link
US (1) US9643931B2 (es)
EP (1) EP3307717B1 (es)
JP (1) JP6891131B2 (es)
KR (1) KR20180006986A (es)
CN (1) CN107690427B (es)
CA (1) CA2987455A1 (es)
ES (1) ES2938053T3 (es)
IL (1) IL255977B (es)
TW (1) TWI613194B (es)
WO (1) WO2016200338A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020260469A1 (en) 2019-06-27 2020-12-30 Synthon B.V. Process for preparation of enzalutamide
CN111217757B (zh) * 2020-01-06 2021-03-19 武汉大学 一种恩杂鲁胺化合物及其药物组合物制剂

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010118354A1 (en) * 2009-04-09 2010-10-14 Medivation Prostate Therapeutics, Inc. Substituted di-arylhydantoin and di-arylthiohydantoin compounds and methods for use thereof
CN103108549A (zh) * 2010-02-24 2013-05-15 梅迪维新前列腺医疗股份有限公司 合成二芳基乙内酰硫脲和二芳基乙内酰脲化合物的方法
CN103910679A (zh) * 2014-04-23 2014-07-09 杭州新博思生物医药有限公司 一种恩杂鲁胺的制备方法
CN106164052A (zh) * 2014-04-07 2016-11-23 赞蒂瓦有限合伙公司 用于制备恩杂鲁胺的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
BRPI1007990A2 (pt) * 2009-02-24 2015-09-01 Medivation Prostate Therapeutics Inc Compostos específicos de diaril-hidantoína e diariltioidantoína.
RU2434851C1 (ru) * 2010-07-22 2011-11-27 Александр Васильевич Иващенко Циклические n, n'-диарилтиомочевины или n, n'-диарилмочевины - антагонисты андрогенных рецепторов, противораковое средство, способ получения и применения
US9611225B2 (en) 2014-01-27 2017-04-04 Cadila Healthcare Limited Process for preparation of androgen receptor antagonist
CN103980141A (zh) * 2014-04-25 2014-08-13 山东大学 恩泽特鲁的合成方法
EP3166931A4 (en) 2014-07-11 2018-05-09 Shilpa Medicare Limited An improved process for the preparation of enzalutamide
CN105461633A (zh) * 2014-07-31 2016-04-06 江苏豪森药业集团有限公司 恩杂鲁胺的制备方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010118354A1 (en) * 2009-04-09 2010-10-14 Medivation Prostate Therapeutics, Inc. Substituted di-arylhydantoin and di-arylthiohydantoin compounds and methods for use thereof
CN103108549A (zh) * 2010-02-24 2013-05-15 梅迪维新前列腺医疗股份有限公司 合成二芳基乙内酰硫脲和二芳基乙内酰脲化合物的方法
CN106164052A (zh) * 2014-04-07 2016-11-23 赞蒂瓦有限合伙公司 用于制备恩杂鲁胺的方法
CN103910679A (zh) * 2014-04-23 2014-07-09 杭州新博思生物医药有限公司 一种恩杂鲁胺的制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Synthesis of bis-3-alkyl-5-arylhydantoins and bis-3-alkyl-5-arylthiohydantoins separated by two and four carbon atoms;O. LeRoy Salerni,等;《Journal of Heterocyclic Chemistry》;19991031;第36卷;第1179-1182页尤其是第1179页 *

Also Published As

Publication number Publication date
CA2987455A1 (en) 2016-12-15
IL255977A (en) 2018-01-31
JP2018516949A (ja) 2018-06-28
US20160362381A1 (en) 2016-12-15
EP3307717A1 (en) 2018-04-18
TWI613194B (zh) 2018-02-01
ES2938053T3 (es) 2023-04-04
KR20180006986A (ko) 2018-01-19
TW201711996A (zh) 2017-04-01
US9643931B2 (en) 2017-05-09
IL255977B (en) 2020-06-30
JP6891131B2 (ja) 2021-06-18
EP3307717A4 (en) 2019-03-27
EP3307717B1 (en) 2023-01-11
WO2016200338A1 (en) 2016-12-15
CN107690427A (zh) 2018-02-13

Similar Documents

Publication Publication Date Title
CN109641891B (zh) 新化合物和方法
CN107690427B (zh) 一种制备恩杂鲁胺的新方法
CN113072436A (zh) 一种苄基芳基醚的制备方法
CN112479890B (zh) 一种硝基化合物的制备方法
CN111517904B (zh) 一种磺酰乙腈类化合物的制备方法
CN113603615B (zh) 一种5-卤代-2[(烷氧基羰基)氨基]-3-甲基苯甲酸的制备方法
CN104045599B (zh) 2-氨基-3-芳基喹啉衍生物的制备方法
TWI845992B (zh) 一種ｂ肝病毒核衣殼抑制劑的製備方法
KR20240038024A (ko) B형 간염 바이러스 뉴클레오캡시드 억제제의 제조 방법
CN112778198A (zh) 一种二氢喹啉酮化合物的合成方法
CN114315793B (zh) 一种利用微通道反应装置制备s-重氮烷烃类化合物的方法
JPS61263995A (ja) シトシンヌクレオシド類の製造法
JPH0558985A (ja) シアノグアニジン誘導体の製造法
EP0259140B1 (en) Cyanoguanidine derivative and process for preparation thereof
CN117865869A (zh) 一种以2-炔基芳胺为原料合成1-三氟甲基吲哚化合物的方法
KR100280423B1 (ko) 전압레벨변환회로
KR100281827B1 (ko) 메틸렌디포스폰산의제조방법
CN113045491A (zh) 一种仑伐替尼及中间体的制备方法
CN116813613A (zh) 一种铑催化的通过吡啶三唑和异氰酸苯酯合成酰胺类化合物的方法
CN117510403A (zh) 一种3-乙基-吡啶-2-甲脒盐酸盐的合成方法
KR19990080727A (ko) N,n-디아실이미다졸론 유도체를 이용한 아민의 아실화 방법
WO2022204947A1 (zh) 一种连接基药物偶联物的制备方法及其中间体
CN117946104A (zh) 一种水相中碘介导的吲哚并[2,3-b]喹啉类化合物的制备方法
CN115710216A (zh) 一种2-磺酰亚胺二氢吡啶衍生物的制备方法
JPWO2010079813A1 (ja) イノシン誘導体の製造方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant